Broadwood Capital Inc.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Broadwood Capital Inc. reported 6 stock positions worth $1.9 billion. Its top holding was Monster Beverage (MNST) at 40.7% of the portfolio, followed by Staar Surgical (STAA, 24.2%) and Axon Enterprise (AXON, 20.3%). Compared with Q1 2026, it added to 1. The biggest buy was Insight Molecular Diagnostic (IMDX, shares +6%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001278387
- Portfolio Value
- $1.9B (Q2 2026)
- SEC Filing
- 0000919574-26-005163 ↗ filed Aug 14, 2026
Holdings Value
Holdings 6 stocks · $1.9B
| MNST Monster Beverage Corp. | 40.73% | 8,107,796 | $779.3M | No change |
| STAA Staar Surgical Co. | 24.18% | 16,123,842 | $462.6M | No change |
| AXON Axon Enterprise Inc. | 20.32% | 693,504 | $388.8M | No change |
| IWM iShares Russell 2000 ETF | 7.46% | 474,920 | $142.7M | No change |
| IMDX Insight Molecular Diagnostic | 3.91% | 12,684,884 | $74.8M | Add +6.3% |
| LCTX Lineage Cell Therapeutics Inc. | 3.39% | 49,560,992 | $64.9M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| None this quarter. | |||
Portfolio Buys Q1 2026 → Q2 2026
| IMDX Insight Molecular Diagnostic | Add +6.3% | 3.91% | +1.15 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $1.9B | MNST, STAA, AXON, IWM, IMDX |
| Q1 2026 | 6 | $1.4B | MNST, STAA, AXON, IWM, LCTX |
| Q4 2025 | 7 | $1.7B | MNST, AXON, STAA, IWM, IMDX |
| Q3 2025 | 7 | $1.7B | MNST, AXON, STAA, IWM, LCTX |
| Q2 2025 | 8 | $1.5B | AXON, MNST, STAA, IWM, LCTX |
| Q1 2025 | 8 | $1.2B | MNST, AXON, STAA, IWM, IMDX |
| Q4 2024 | 7 | $1.3B | MNST, AXON, STAA, IWM, LCTX |
| Q3 2024 | 7 | $1.3B | MNST, STAA, AXON, IWM, LCTX |
| Q2 2024 | 7 | $1.3B | STAA, MNST, AXON, IWM, LCTX |
| Q1 2024 | 7 | $1.3B | MNST, STAA, AXON, IWM, LCTX |